Postnatal induction of transforming growth factor β signaling in fibroblasts of mice recapitulates clinical, histologic, and biochemical features of scleroderma
Open Access
- 2 January 2007
- journal article
- research article
- Published by Wiley in Arthritis & Rheumatism
- Vol. 56 (1) , 334-344
- https://doi.org/10.1002/art.22328
Abstract
Objective: Increased signaling by transforming growth factor β (TGFβ) has been implicated in systemic sclerosis (SSc; scleroderma), a complex disorder of connective tissues characterized by excessive accumulation of collagen and other extracellular matrix components in systemic organs. To directly assess the effect of sustained TGFβ signaling in SSc, we established a novel mouse model in which the TGFβ signaling pathway is activated in fibroblasts postnatally.Methods: The mice we used (termed TBR1CA; Cre‐ER mice) harbor both the DNA for an inducible constitutively active TGFβ receptor I (TGFβRI) mutation, which has been targeted to theROSAlocus, and a Cre‐ER transgene that is driven by a fibroblast‐specific promoter. Administration of 4‐hydroxytamoxifen 2 weeks after birth activates the expression of constitutively active TGFβRI.Results: These mice recapitulated clinical, histologic, and biochemical features of human SSc, showing pronounced and generalized fibrosis of the dermis, thinner epidermis, loss of hair follicles, and fibrotic thickening of small blood vessel walls in the lung and kidney. Primary skin fibroblasts from these mice showed elevated expression of downstream TGFβ targets, reproducing the hallmark biochemical phenotype of explanted SSc dermal fibroblasts. The mouse fibroblasts also showed elevated basal expression of the TGFβ‐regulated promoters plasminogen activator inhibitor 1 and 3TP, increased Smad2/3 phosphorylation, and enhanced myofibroblast differentiation.Conclusion: Constitutive activation of TGFβ signaling in fibroblastic cells of mice after birth caused a marked fibrotic phenotype characteristic of SSc. These mice should be excellent models with which to test therapies aimed at correcting excessive TGFβ signaling in human scleroderma.Keywords
This publication has 38 references indexed in Scilit:
- Matrix Contraction by Dermal Fibroblasts Requires Transforming Growth Factor-β/Activin-Linked Kinase 5, Heparan Sulfate-Containing Proteoglycans, and MEK/ERKThe American Journal of Pathology, 2005
- Analysis of the tight skin (Tsk1/+) mouse as a model for testing antifibrotic agentsLaboratory Investigation, 2005
- Ligand-Dependent Genetic Recombination in FibroblastsThe American Journal of Pathology, 2002
- Transforming growth factor-β and connective tissue growth factor: key cytokines in scleroderma pathogenesisCurrent Opinion in Rheumatology, 2001
- Markers of joint destruction: principles, problems, and potentialAnnals of the Rheumatic Diseases, 2001
- Identification of multiple, differentially expressed messenger RNAs in dermal fibroblasts from patients with systemic sclerosisArthritis & Rheumatism, 1999
- Animal Model of Sclerotic Skin. I: Local Injections of Bleomycin Induce Sclerotic Skin Mimicking SclerodermaJournal of Investigative Dermatology, 1999
- Regulation of Cre Recombinase Activity by Mutated Estrogen Receptor Ligand-Binding DomainsBiochemical and Biophysical Research Communications, 1997
- A potent far-upstream enhancer in the mouse pro alpha 2(I) collagen gene regulates expression of reporter genes in transgenic mice.The Journal of cell biology, 1996
- The tight skin 2 mouseArthritis & Rheumatism, 1995